Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models | Zendy

Thierry Menguy | Zendy; Anne Briaux | Zendy; Élisabeth Jeunesse | Zendy; Jérôme Giustiniani | Zendy; Alexandre Calcei | Zendy; Thierry Guyon | Zendy; Jacques Mizrahi | Zendy; Hélène Haegel | Zendy; Vanessa Duong | Zendy; Vincent Soler | Zendy; Pierre Brousset | Zendy; Armand Bensussan | Zendy; Isabelle RaymondLetron | Zendy; Philippe Le Bouteiller | Zendy

Open Access

Anti-CD160, Alone or in Combination With Bevacizumab, Is a Potent Inhibitor of Ocular Neovascularization in Rabbit and Monkey Models

Author(s) -

Thierry Menguy,

Anne Briaux,

Élisabeth Jeunesse,

Jérôme Giustiniani,

Alexandre Calcei,

Thierry Guyon,

Jacques Mizrahi,

Hélène Haegel,

Vanessa Duong,

Vincent Soler,

Pierre Brousset,

Armand Bensussan,

Isabelle RaymondLetron,

Philippe Le Bouteiller

Publication year - 2018

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.18-24024

Subject(s) - bevacizumab , neovascularization , pharmacology , ophthalmology , medicine , angiogenesis , cancer research , surgery , chemotherapy

To assess the efficacy of the murine first-in-class CL1-R2 monoclonal antibody (mAb) targeting human CD160 (alone or in combination with bevacizumab) by using the rabbit corneal neovascularization (CNV) model, and determine the safety and efficacy of ELB01101, a novel CL1-R2-derived humanized IgG4 mAb, in a monkey model of choroidal neovascularization (ChNV).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research